Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Northwest Biotherapeutics Inc (NWBO)
Price$0.16965Cached quote
Net income
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $1.4M | $1.9M | $1.7M | $1.0M | $1.3M | $2.4M | $412,000 | $336,000 | $623,000 | $1.7M | $1.5M | $809,000 | $772,000 | $10,000 | $10,000 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | $809,000 | $772,000 | $10,000 | $10,000 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — | 100.00% | 100.00% | 100.00% | 100.00% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $28.8M | $34.9M | $27.7M | $35.5M | $20.3M | $33.6M | $14.1M | $18.2M | $33.5M | $60.1M | $103.1M | $85.6M | $43.9M | $28.9M | $13.5M | $9.9M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $61.3M | $67.9M | $57.4M | $68.9M | $53.7M | $87.9M | $30.4M | $45.2M | $55.0M | $79.9M | $128.0M | $102.6M | $56.3M | $44.6M | $26.8M | $15.4M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$59.9M | −$66.5M | −$55.5M | −$67.2M | −$52.7M | −$86.6M | −$28.0M | −$41.5M | −$54.7M | −$79.3M | −$126.3M | −$101.1M | −$55.5M | −$43.8M | −$26.8M | −$15.4M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −4,347.90% | −4,812.45% | −2,873.08% | −3,991.74% | −5,243.98% | −6,708.37% | −1,160.95% | −10,068.20% | −16,273.21% | −12,723.27% | −7,261.87% | −6,956.19% | −6,857.11% | −5,676.81% | −267,870.00% | −153,540.00% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$57.9M | −$64.8M | −$54.0M | −$65.9M | −$52.4M | −$86.5M | −$28.0M | −$40.2M | −$54.2M | −$79.1M | −$126.2M | −$101.1M | −$55.5M | −$43.8M | −$26.8M | −$15.4M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA margin | −4,198.11% | −4,686.25% | −2,794.15% | −3,917.35% | −5,211.74% | −6,701.63% | −1,160.08% | −9,754.85% | −16,142.56% | −12,692.94% | −7,258.65% | −6,955.43% | −6,855.75% | −5,675.00% | −267,770.00% | −153,520.00% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$60.2M | −$83.8M | −$62.6M | −$105.0M | $179.1M | −$529.8M | −$20.8M | −$35.8M | −$73.1M | −$80.2M | −$114.7M | −$135.6M | −$65.8M | −$67.3M | −$32.8M | −$27.4M | −$27.0M | −$22.3M | −$21.2M | −$1.4M | −$9.9M | −$8.5M | −$5.8M | −$12.8M | −$10.9M | −$12.8M | −$5.6M | −$4.7M | −$2.6M |
| Net profit margin | −4,365.89% | −6,062.08% | −3,240.11% | −6,240.76% | 17,823.48% | −41,039.58% | −863.57% | −8,687.86% | −21,768.75% | −12,875.44% | −6,598.10% | −9,328.34% | −8,132.14% | −8,720.21% | −328,300.00% | −273,680.00% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$0.04 | -$0.07 | -$0.06 | -$0.10 | $0.21 | -$0.73 | -$0.04 | -$0.12 | -$0.31 | -$0.77 | -$1.48 | -$2.29 | -$2.00 | -$5.72 | -$5.60 | -$6.56 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$0.04 | -$0.07 | -$0.06 | -$0.10 | -$0.06 | -$0.73 | -$0.04 | -$0.12 | -$0.31 | -$0.77 | -$1.48 | -$2.29 | -$2.00 | -$5.72 | -$5.58 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Owners
Reported shareholders
0.07%of listed shares
COMPASS FINANCIAL MANAGEMENT LLC1.22M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
COMPASS FINANCIAL MANAGEMENT LLC | 0.07%1.22M shares |
KELLEHER FINANCIAL ADVISORS | 0.05%800K shares |
VSM Wealth Advisory, LLC | <0.01%80.57K shares |
Opus Capital Group, LLC | <0.01%60.15K shares |
Ethos Financial Group, LLC | <0.01%39.07K shares |
Williams Jones Wealth Management, LLC. | <0.01%25K shares |
Coston, McIsaac & Partners | <0.01%1K shares |
HANTZ FINANCIAL SERVICES, INC. | <0.01%250 shares |
Percentages use 1.67B shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 26, 2024Form 4 | MALIK NAVIDDirector | SellStock Option · derivative | 657.9K | $0.38 | $250.0K | 23.34M |